Deal With Gilead For Anti-CD123 Bispecific Offers Breath Of Fresh Air For MacroGenics

 
• By Alaric DeArment
  
Gilead and MacroGenics announced a deal worth potentially more than $1.7bn focused on an anti-CD123 bispecific antibody • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business